Is N-Acetyl Selank Amidate approved as a medicine, and where?

The regulatory review of N-Acetyl Selank Amidate is incomplete. See the article's sources for product- and country-specific findings and remaining uncertainties. Review status means neither worldwide approval nor worldwide absence of approval.

Does N-Acetyl Selank Amidate have human clinical trials?

The evidence review of N-Acetyl Selank Amidate is in progress. The article's study appraisal identifies any human studies located and their limitations. An ongoing review does not itself mean that human studies are absent.

Index by category›

Nootropic & Neuropeptides

N-Acetyl Selank Amidate

Name: N-Acetyl Selank Amidate
Creator: PeptideInfo Wiki editorial collective
Published: 2026-10-07

NA-Selank Amidate; NA-Selank; N-acetyl selank amidate; Ac-Selank-NH2

2 min read · Updated October 7, 2026 · 4 references

Curated by PeptideInfo Wikilast reviewed October 7, 2026how we verify

In brief · TL;DR

Source record — verification pending

Research-chemical Selank analogue (Ac + NH2) with no registry CID for the amidate and no PubMed hits. CID 133082488 is N-acetyl free acid — not the amidate. All marketing evidence is parent-Selank extrapolation. No dose.

Evidence: Catalog coverage only; independent identity, evidence and regulatory review is still pending.

Intended chemistry: Ac-Thr-Lys-Pro-Arg-Pro-Gly-Pro-NH2; typical calculated formula ~C35H60N12O9 / MW ~792.9 — vendor/secondary, not an authenticated registry deposit
No PubChem CID for N-Acetyl Selank Amidate (name lookup NotFound, 2026-10-07)
CRITICAL: CID 133082488 is N-Acetyl Selank free acid (C35H59N11O10) — NOT the C-amide
Zero PubMed hits for NA-Selank / N-Acetyl Selank Amidate; parent Selank evidence stays on the Selank page
Parent Selank is Russia-registered — that status does NOT apply to this variant

↓ Read the full referenced entry below

Facts at a glance

N-Acetyl Selank Amidate

Class: Double-capped synthetic heptapeptide analogue of Selank (Ac + C-amide; vendor-defined)
Status: Research chemical — exact amidate lacks registry ID and peer-reviewed pharmacology; editorial review pending
Sequence: Ac-Thr-Lys-Pro-Arg-Pro-Gly-Pro-NH2 (intended caps; not authenticated against a PubChem amidate record)
Mol. weight: Often stated ~792.9 (calculated C35H60N12O9) — unverified registry. Do not use CID 133082488 (free acid, 793.9, C35H59N11O10) as the amidate.
Half-life: Not established for this exact analog — no peer-reviewed PK identified
Form: Research powder / vendor research peptide (not a registered medicine)

Dosing

No established dose. No approved or trial-defined regimen exists for N-Acetyl Selank Amidate. No vendor or parent-Selank dose is reproduced here.

Research areas

Peptide capping hypotheses (unverified for this exact analog) · Parent Selank anxiolytic/nootropic literature — see Selank page; not transferable by default

N-Acetyl Selank Amidate is a vendor-defined double-capped Selank analogue (N-acetyl + C-terminal amide) with no verified PubChem CID or CAS for the exact amidate form and zero identified peer-reviewed pharmacology. Do not confuse PubChem CID 133082488 (N-acetyl free acid) with the amidate. Russian Selank approval does not apply.

Body & signals →

No receptor relationship mapped here yet. This does not mean the molecule has no biological effects.

Review pending

Contents6

Editorial review pending — noindex

This page remains under independent editorial review (reviewPending). Visible but noindexed.

No peer-reviewed data on this exact analog

Zero PubMed hits for N-Acetyl Selank Amidate / NA-Selank were identified (2026-10-07). Parent Selank studies and Russian registration do not transfer.

Do not confuse CID 133082488 with the amidate

PubChem CID 133082488 is N-Acetyl Selank free acid (C₃₅H₅₉N₁₁O₁₀, MW 793.9) — not the C-terminal amide. Name lookup for “N-Acetyl Selank Amidate” returned NotFound. Do not alias the free-acid CID as the amidate product.

Section 1 of 6Overview

Overview

N-Acetyl Selank Amidate (NA-Selank Amidate) is a vendor-defined Selank analogue intended as Ac-Thr-Lys-Pro-Arg-Pro-Gly-Pro-NH₂ (N-acetyl + C-amide). Unlike NA-Semax Amidate, this form lacks a verified PubChem CID/CAS in the dossier search. Formula/MW figures (~C₃₅H₆₀N₁₂O₉ / ~792.9) are calculated/secondary until a registry deposit exists.

Section 2 of 6Parent vs this variant

Parent vs this variant

	Selank (parent)	N-Acetyl Selank Amidate	N-Acetyl Selank free acid
Caps	Free termini	Ac- … -NH₂ (intended)	Ac- … -OH
PubChem	CID 11765600	None (NotFound)	CID 133082488
Formula	C₃₃H₅₇N₁₁O₉ · ~751.9	~C₃₅H₆₀N₁₂O₉ · ~792.9 (calc.)	C₃₅H₅₉N₁₁O₁₀ · 793.9
Regulatory	Registered in Russia; not FDA/EMA	None	Not this page’s subject

Section 3 of 6Literature search

Literature search

Source	Result
PubMed NA-Selank / N-Acetyl Selank Amidate / “N-acetyl” AND Selank	0 hits for the variant
PubMed Selank[Title] (parent)	Dozens — stay on Selank
ClinicalTrials.gov for amidate variant	None identified
PubChem name “N-Acetyl Selank Amidate”	NotFound

PMID 31667971 (Vanhee 2020) may document grey-market “cognitive” research peptides analytically — not an efficacy study of this amidate.

Section 4 of 6Claims vs evidence

Claims vs evidence

Claim	Assessment
Double-capped Selank analogue	Supported as chemical intent (vendor/secondary) — weak registry
Better / longer Selank	Not verified
Same anxiolysis/GABA/BDNF as Selank	Extrapolation from parent only
CID 133082488 = NA-Selank Amidate	False / mix-up — free acid
RU/FDA/EMA approved	False for the variant
Vendor dose	Reject

Section 5 of 6Related pages

Parent: Selank
Parallel research-chemical Semax line: N-Acetyl Semax Amidate

Section 6 of 6What this page intentionally omits

What this page intentionally omits

Any dose or protocol
Copying Selank clinical results onto the amidate
Treating free-acid CID 133082488 as the amidate identity

References4

References

1.
PubChem CID 11765600 — Selank (parent) source
2.
PubChem CID 133082488 — N-Acetyl Selank free acid (NOT the amidate) source
3.
Putative cognitive-enhancing research peptides in seizures (analytical) — Vanhee C, et al., 2020. source
4.
PeptideInfo — Selank (parent) source

Frequently asked questions4

Frequently asked questions

What is N-Acetyl Selank Amidate?: N-Acetyl Selank Amidate is a vendor-defined double-capped Selank analogue (N-acetyl + C-terminal amide) with no verified PubChem CID or CAS for the exact amidate form and zero identified peer-reviewed pharmacology. Do not confuse PubChem CID 133082488 (N-acetyl free acid) with the amidate. Russian Selank approval does not apply.
Is N-Acetyl Selank Amidate approved as a medicine, and where?: The regulatory review of N-Acetyl Selank Amidate is incomplete. See the article's sources for product- and country-specific findings and remaining uncertainties. Review status means neither worldwide approval nor worldwide absence of approval.
What is N-Acetyl Selank Amidate studied for?: Research has examined Peptide capping hypotheses (unverified for this exact analog) and Parent Selank anxiolytic/nootropic literature — see Selank page; not transferable by default. Being studied for an area does not mean it is proven or approved for it.
Does N-Acetyl Selank Amidate have human clinical trials?: The evidence review of N-Acetyl Selank Amidate is in progress. The article's study appraisal identifies any human studies located and their limitations. An ongoing review does not itself mean that human studies are absent.

Educational disclaimer. This article summarizes published research for informational purposes and is not medical advice. The editorial review of N-Acetyl Selank Amidate is incomplete. Source-supported findings and remaining uncertainties are stated in the article; review status does not certify approval, safety or suitability for use. Consult a qualified healthcare professional before making health decisions.